![Rainer Wessel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rainer Wessel
Private Equity Investor chez
EMBL Ventures GmbH
Profil
Rainer Wessel is currently a Venture Partner at EMBL Ventures GmbH.
Previously, he worked as the President & Chief Executive Officer at Axxima Pharmaceuticals AG.
He also served as the Chief Business Officer & Executive Speaker at Ganymed Pharmaceuticals AG from 2009 to 2011.
Additionally, he worked as a Principal at QIAGEN GmbH.
Postes actifs de Rainer Wessel
| Sociétés | Poste | Début |
|---|---|---|
EMBL Ventures GmbH
 EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept. | Private Equity Investor | - |
Anciens postes connus de Rainer Wessel
| Sociétés | Poste | Fin |
|---|---|---|
Ganymed Pharmaceuticals AG
 Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | President | 05/11/2009 |
QIAGEN GmbH
 QIAGEN GmbH Miscellaneous Commercial ServicesCommercial Services Provides products for preanalytical sample preparation and molecular diagnostics solutions | Corporate Officer/Principal | - |
Axxima Pharmaceuticals AG
 Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Researches and develops drugs | President | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
2
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Ganymed Pharmaceuticals AG
Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Develops antibodies for the treatment of solid cancers | Health Technology |
Axxima Pharmaceuticals AG
Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Researches and develops drugs | Commercial Services |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept. | Finance |
QIAGEN GmbH
QIAGEN GmbH Miscellaneous Commercial ServicesCommercial Services Provides products for preanalytical sample preparation and molecular diagnostics solutions | Commercial Services |
